| Document Date: 2011-08-15 11:58:22
Open Document File Size: 70,99 KBShare Result on Facebook
City SEATTLE / / Company De Novo Ventures / HemaQuest Pharmaceuticals / Lilly Ventures / Forward Ventures / Beta Thalassemia Venture / / Continent Europe / / Country Thailand / United States / / Event Funding / / Facility Boston University / / IndustryTerm treatment of patients with sickle cell disease / biopharmaceutical / globin chain / Therapy for Common Life‐threatening Genetic Disorders / / MedicalCondition hemoglobin disorders / Common Life‐threatening Genetic Disorders / chronic illnesses / strokes / prevalent blood disease / cancer / disease / Chronic damage / acute chest syndrome / genetic disorder / both sickle cell disease / severe anemia / pain / hematologic disorders / lung injury / Sickle Cell Disease / beta thalassemia / hemoglobin diseases / disorders / / MedicalTreatment red blood cell transfusions / chemotherapy / / Organization Boston University / / Person Ron Berenson / / Position President and Chief Executive Officer / / Product hydroxyurea / SCFADs / / Technology SCFAD technologies / chemotherapy / / URL www.HemaQuest.com / /
SocialTag |
Microsoft Word - HemaQuest Pharmaceuticals - Commencing Sickle Cell and Beta Thalassemia clinical trials _5-26-2009_